Free Trial

MetLife (MET) Stock Forecast & Price Target

MetLife logo
$79.51 -2.24 (-2.74%)
Closing price 09/5/2025 03:59 PM Eastern
Extended Trading
$79.30 -0.21 (-0.27%)
As of 09/5/2025 07:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MetLife - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
0
Hold
1
Buy
10

Based on 11 Wall Street analysts who have issued ratings for MetLife in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 11 analysts, 1 has given a hold rating, and 10 have given a buy rating for MET.

Consensus Price Target

$95.60
20.24% Upside
According to the 11 analysts' twelve-month price targets for MetLife, the average price target is $95.60. The highest price target for MET is $103.00, while the lowest price target for MET is $91.00. The average price target represents a forecasted upside of 20.24% from the current price of $79.51.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for MET and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for MetLife and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MET Analyst Ratings Over Time

TypeCurrent Forecast
9/6/24 to 9/6/25
1 Month Ago
8/7/24 to 8/7/25
3 Months Ago
6/8/24 to 6/8/25
1 Year Ago
9/7/23 to 9/6/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
10 Buy rating(s)
10 Buy rating(s)
12 Buy rating(s)
12 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$95.60$95.40$94.17$84.54
Forecasted Upside20.24% Upside29.30% Upside17.72% Upside14.12% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

MET Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MET Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

MetLife Stock vs. The Competition

TypeMetLifeFinance CompaniesS&P 500
Consensus Rating Score
2.91
2.53
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside20.24% Upside17.10% Upside10.36% Upside
News Sentiment Rating
Positive News

See Recent MET News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
8/22/2025Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingBuy
8/18/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Nigel Dally
Not Rated
Lower TargetOverweight$98.00 ➝ $94.00+21.99%
8/11/2025Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Suneet Kamath
Not Rated
Boost TargetBuy$100.00 ➝ $103.00+35.08%
8/11/2025Keefe, Bruyette & Woods
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetOutperform$94.00 ➝ $92.00+20.66%
8/7/2025UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetBuy$94.00 ➝ $91.00+23.65%
7/10/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$94.00 ➝ $97.00+23.76%
7/8/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$86.00 ➝ $95.00+18.68%
7/7/2025Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$88.00 ➝ $94.00+18.63%
4/2/2025Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$92.00 ➝ $94.00+14.87%
1/23/2025BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageMarket Perform$97.00+13.09%
11/27/2024TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$97.00 ➝ $99.00+11.50%
8/1/2024Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetBuy$99.00 ➝ $96.00+24.92%
7/23/2024Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy$83.00 ➝ $89.00+18.26%
5/22/2024Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy$77.00 ➝ $80.00+9.50%
1/8/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeNeutralBuy$70.00 ➝ $80.00+16.08%
10/4/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Initiated CoverageHold$71.00+18.33%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 05:28 PM ET.


Should I Buy MetLife Stock? MET Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, September 5, 2025. Please send any questions or comments about these MetLife pros and cons to contact@marketbeat.com.

MetLife
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in MetLife, Inc.:

  • Recent analyst upgrades have increased the price target for MetLife, Inc. to around $95.60, indicating strong potential for growth.
  • The current stock price is approximately $78.93, which may present a buying opportunity given the positive outlook from analysts.
  • MetLife, Inc. has a solid market capitalization of about $52.49 billion, reflecting its stability and presence in the financial services sector.
  • The company has a consistent dividend payout, with a recent quarterly dividend of $0.5675 per share, translating to an annual yield of about 2.9%, which can provide income to investors.
  • Ten analysts have rated the stock as a Buy, showcasing strong confidence in the company's future performance.

MetLife
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in MetLife, Inc. for these reasons:

  • MetLife, Inc. reported earnings per share (EPS) of $2.02, which fell short of the consensus estimate of $2.32, indicating potential challenges in meeting financial expectations.
  • The company's revenue for the latest quarter was down about 2.7% year-over-year, suggesting a decline in business performance.
  • With a current ratio of 0.16, MetLife, Inc. may face liquidity issues, as this ratio indicates that current liabilities significantly exceed current assets.
  • The stock has experienced fluctuations, with a 1-year low of $65.21 and a high of $89.05, which may indicate volatility and risk for investors.
  • Despite a strong market presence, the company's net margin of 5.83% may suggest limited profitability compared to competitors in the financial services industry.

MET Forecast - Frequently Asked Questions

According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for MetLife is $95.60, with a high forecast of $103.00 and a low forecast of $91.00.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MetLife in the last year. There is currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" MET shares.

According to analysts, MetLife's stock has a predicted upside of 20.24% based on their 12-month stock forecasts.

MetLife has been rated by research analysts at Barclays, Cowen, Jefferies Financial Group, JPMorgan Chase & Co., Keefe, Bruyette & Woods, Morgan Stanley, UBS Group, and Wells Fargo & Company in the past 90 days.

Analysts like MetLife more than other "finance" companies. The consensus rating score for MetLife is 2.91 while the average consensus rating score for "finance" companies is 2.53. Learn more on how MET compares to other companies.


This page (NYSE:MET) was last updated on 9/6/2025 by MarketBeat.com Staff
From Our Partners